Monash IVF Group Ltd (ASX:MVF) shares plunge 10% on sizeable drop in profits

In morning trade the Monash IVF Group Ltd (ASX: MVF) share price has tumbled lower by over 10% to $1.15 following the release of its results for the 12 months ended June 30.

In FY 2018 the fertility treatment company posted revenue of $150.6 million, earnings before interest, tax, depreciation and amortisation (EBITDA) of $38.1 million, and net profit after tax of $21.4 million. This was a decline of 2.9%, 22.2%, and 27.9%, respectively, on the prior corresponding period.

Basic earnings per share was 27.8% lower year-on-year at 9.1 cents, leading to the Monash IVF board slashing its full year dividend by 31.8% to 6 cents per share.

Source: Company presentation

As you can see above, the main cause of the company’s revenue decline in FY 2018 was the loss of its key Victorian fertility specialist, Dr Lynn Burmeister. This offset its market share gains, favourable price/mix from its assisted reproductive services (ARS), and growth in its International ARS and Ultrasound & Diagnostics segments.

It was Dr Burmeister’s exit that also weighed on its margins and profits in FY 2018. Monash IVF’s EBITDA margin fell from 31.6% in FY 2017 to 25.3% in FY 2018 due to leverage impact from volume decline in Victoria. An increase in its cost base from $106.3 million to $112.5 million also added pressure to its margins.

The table below demonstrates the impact that Dr Burmeister’s exit has had on patient treatments in FY 2018.

Source: Company presentation

Although the company is expected to return to growth in FY 2019, it won’t be until the second half of the year according to management. Due to Dr Lynn Burmeister operating for one quarter in the prior corresponding period, net profit after tax in the first half is expected to decline by 15%.

Should you invest?

While Monash IVF may be over the worst of it now, I intend to keep my powder dry until at least the release of its first half results. At that point investors should be able to see whether the company returned to growth in the second quarter when comparisons became fairer.

In the meantime rival Virtus Health Ltd (ASX: VRT) could be worth a look or even pharmaceutical company Mayne Pharma Group Ltd (ASX: MYX).

Alternatively, I think that these top growth shares could be even better investment options.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Monash IVF Group Ltd and Virtus Health Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.